SHANGHAI, May 8, 2020 /PRNewswire/ -- 111, Inc. ("111" or
the "Company") (Nasdaq: YI), a leading integrated online and
offline healthcare platform in China, today announced that it is launching a
new diabetes patient management platform in cooperation with
Lilly China.
The two companies will work together to build a comprehensive
diabetes patient management platform that includes services such as
disease management, disease education and patient support programs
to enrich patients' knowledge of chronic disease management and to
better help diabetic patients to self-manage from home. The
platform will seek to harness the power of internet hospital
technologies, big data and artificial intelligence technologies to
provide diabetic patients with a comprehensive digital health
management solution.
111 has accumulated extensive experience in operations
management in the area of chronic disease, especially in diabetes,
laying a solid foundation for the development of the diabetes
management platform. With the transformative power of technology,
the platform will seek to provide patients with a one-stop solution
for "physician consultation + medication" services, allowing
patients to consult with qualified physicians online, and receive
personalized healthcare management services, online refill service,
and medication delivery services.
As the first multinational pharmaceutical company to join the
platform, Lilly China will leverage
its expertise in the field of diabetes management and will also
offer a variety of patient management and support programs,
including "Lilly Connected Care Program" and Patient Benefit
Program, to eligible diabetes patients, with the aim of providing
personalized disease education and health management services. In
addition, with its deep experience in the diabetes field,
Lilly China will help to develop a
directory of disease education resources to help patients
understand risk factors, signs and symptoms, and treatment
options.
Commenting on Lilly's collaboration with 111, President and
General Manager of Lilly China, Mr.
Julio Gay-Ger, said, "The internet +
healthcare model has increasingly gained recognition from the
Chinese government, and Lilly China
is actively exploring innovative business models in collaboration
with a number of third-party platforms, including internet
hospitals. Joining 111's diabetes patient platform is an
opportunity for Lilly China to
conduct disease management and education through online hospitals,
and also improve access to Lilly
China's various patient support and benefit programs for
diabetic patients."
"China has over 100 million diabetic patients, and it is crucial
to help this large group of patients to manage their health
effectively," said Dr. Yu Gang,
Co-Founder and Executive Chairman of 111. "As a technology enabler
of the pharmaceutical health ecosystem, 111 looks forward to
working with Lilly China to leverage
resources and core competence in each of our respective fields, and
explore an efficient management model of diabetes. This
collaboration aims to deliver better care and medical outcomes for
patients with chronic diseases by developing an integrated digital
health management platform. Our ambition is to leverage on
technology to overcome the constraints of time and location to
provide greater convenience for both patients and physicians," Dr.
Yu Gang noted. "Through our
platform, we hope to provide patients with better access to
information on diet, exercise, and medication specifically tailored
to their individual needs, as well as a personalized management and
treatment program that could help improve their own health. A step
closer to the goals of Healthy China 2030."
About 111, Inc.
111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading
integrated online and offline healthcare platform in China. The Company provides hundreds of
millions of consumers with better access to pharmaceutical products
and healthcare services directly through its online retail pharmacy
and indirectly through its offline pharmacy network. 111 also
offers online healthcare services through its internet hospital, 1
Clinic, which provides consumers with cost-effective and convenient
online consultation and electronic prescription services. In
addition to providing direct services to consumers through its
online retail pharmacy, 111 also enables offline pharmacies to
better serve their customers. The Company's online wholesale
pharmacy, 1 Drug Mall, serves as a one-stop shop for pharmacies to
source a vast selection of pharmaceutical products. The Company's
new retail platform, by integrating the front and back ends of the
pharmaceutical supply chain, has formed a smart supply chain, which
transforms the flow of pharmaceutical products to pharmacies and
modernizes how they serve their customers.
For more information on 111, please visit
http://ir.111.com.cn/.
For more information, please contact:
111, Inc.
Media Relations
Email: press@111.com.cn
Phone: +86-021-2053 6666 (China)
111, Inc.
Investor Relations
Email: ir@111.com.cn
GCM Strategic Communications
IR Counsel
Email: 111.ir@gcm.international
View original
content:http://www.prnewswire.com/news-releases/111-to-launch-first-online-diabetes-patient-management-platform-with-lilly-china-301055612.html
SOURCE 111, Inc.